Insmed (INSM) Profit After Tax Growth (3y) (2013 - 2026)
Insmed (INSM) Profit After Tax Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 9.53% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -27.65% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 70.25% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Insmed | 22.60 Bn | 21.38 Bn | 258.54 Mn | 79.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 79.09% |
| Dec 31, 2025 | -27.20% |
| Sep 30, 2025 | -41.14% |
| Jun 30, 2025 | 79.34% |
| Mar 31, 2025 | -39.45% |
| Dec 31, 2024 | 18.24% |
| Sep 30, 2024 | -779.64% |
| Jun 30, 2024 | -866.21% |
| Mar 31, 2024 | -19.68% |
| Dec 31, 2023 | 43.03% |
| Sep 30, 2023 | -80.71% |
| Jun 30, 2023 | -58.14% |
| Mar 31, 2023 | -33.93% |
| Dec 31, 2022 | -43.86% |
| Sep 30, 2022 | -4,986.52% |
| Jun 30, 2022 | 78.10% |
| Mar 31, 2022 | -8.48% |
| Dec 31, 2021 | -67.95% |
| Sep 30, 2021 | 84.54% |
| Jun 30, 2021 | 26.08% |